Different signalling pathways regulate VEGF and IL-8 expression in breast cancer: Implications for therapy

European Journal of Cancer

Volumn 40, Issue 16, 2004, Pages 2509-2518

  Chelouche Lev, Dina ^a   Miller, Claudia P ^a   Tellez, Carmen ^a   Ruiz, Maribelis ^a   Bar Eli, Menashe ^a   Price, Janet E ^a  

^a NONE

Author keywords

Angiogenic cytokines; Breast cancer; Mitogen activated protein kinase; Phosphatidylinositol 3 kinase

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; 2 MORPHOLINO 8 PHENYLCHROMONE; CYTOKINE; INTERLEUKIN 8; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; VASCULOTROPIN;

ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER SURVIVAL; CANCER THERAPY; CELL LINE; CONTROLLED STUDY; DOWN REGULATION; ENZYME INHIBITION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TUMOR GROWTH;

1-PHOSPHATIDYLINOSITOL 3-KINASE; BREAST NEOPLASMS; CELL COMMUNICATION; CELL LINE, TUMOR; DNA; ENZYME-LINKED IMMUNOSORBENT ASSAY; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FEMALE; HUMANS; INTERLEUKIN-8; NEOPLASM PROTEINS; NF-KAPPA B; PHOSPHORYLATION; POLYMERASE CHAIN REACTION; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-AKT; TRANSCRIPTION FACTOR AP-1; TRANSFECTION; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 7044234484     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2004.05.024     Document Type: Article

References (45)

1. N. Weidner, J.P. Semple, W.R. Welch, and J. Folkman Tumor angiogenesis and metastasis - correlation in invasive breast carcinoma N. Engl. J. Med. 324 1991 3 8
2. G. Gasparini Clinical significance of determination of surrogate markers of angiogenesis in breast cancer Crit. Rev. Oncol./Hematol. 37 2001 3 114
3. D.R. Senger, L. Van De Water, and L.F.B. Brown Vascular permeability factor (VPF,VEGF) in tumor biology Cancer Metast. Rev. 12 1993 303 324
4. J.H. Harmey, and D. Bouchier-Hayes Vascular endothelial growth factor (VEGF), a survival factor for tumor cells: implications for anti-angiogenic therapy BioEssays 24 2002 280 283
5. D.J. Price, T. Miralem, S. Jiang, R. Steinberg, and H. Avraham Role of vascular endothelial growth factor in the stimulation of cellular invasion and signaling of breast cancer cells Cell Growth Differ. 12 2001 129 135
6. M. Bar-Eli Role of interleukin-8 in tumor growth and metastasis in human melanoma Pathobiology 67 1999 3 18
7. A. Freund, C. Chauveau, and J.P. Brouillet IL-8 expression and its possible relationship with estrogen-receptor-negative status of breast cancer cells Oncogene 22 2003 256 265
8. Y. Lin, R. Huang, and L. Chen Identification of interleukin-8 as estrogen receptor-regulated factor involved in breast cancer invasion and angiogenesis by protein arrays Int. J. Cancer 109 2004 507 515
9. A. Ben-Baruch Host microenvironment in breast cancer development: inflammatory cells, cytokines and chemokines in breast cancer progression: reciprocal tumor-microenvironment interactions Breast Cancer Res. 5 2002 31 36
10. A.B. Alexandroff, A.M. Jackson, and T. Paterson Role for CD40-CD40 ligand interactions in the immune response to solid tumors Mol. Immunol. 37 2000 515 526
11. D.R. Green, V.L. Green, M.C. White, and V. Speirs Expression of cytokine messenger RNA in normal and neoplastic human breast tissue: identification of interleukin-8 as a potential regulatory factor in breast cancer Int. J. Cancer 72 1997 937 941
12. J.E. De Larco, B.R.K. Wuertz, and K.A. Rosner A potential role for interleukin-8 in the metastatic phenotype of breast carcinoma cells Am. J. Pathol. 158 2001 639 646
13. S. Nishimura, N. Maeno, and K. Matsuo Human lactiferous mammary gland cells produce vascular endothelial growth factor (VEGF) and express the VEGF receptors, Flt-1 and KDR/Flk-1 Cytokine 18 2002 191 198
14. A.S. Goldman, S. Chheda, R. Garofalo, and F.C. Schmalstieg Cytokines in human milk: properties and potential effects upon the mammary gland and the neonate J. Mammary Gland Biol. Neoplasia 1 1996 251 258
15. A.L. Harris Hypoxia - a key regulatory factor in tumor growth Nat. Rev. Cancer 2 2002 38 47
16. C.C. Bancroft, Z. Chen, and G. Dong Coexpression of proangiogenic factors IL-8 and VEGF by human head and neck squamous cell carcinoma involves coactivation by MEK-MAPK and IKK-NF-κB signal pathways Clin. Cancer Res. 7 2001 435 442
17. E. Berra, G. Pages, and J. Pouyssegur MAP kinases and hypoxia in the control of VEGF expression Cancer Metast. Rev. 19 2000 139 145
18. Y. Osawa, M. Nagaki, and Y. Banno Tumor necrosis factor alpha-induced interleukin-8 production via NF-kappaB and phosphatidylinosotol 3-kinase/Akt pathways inhibits cell apoptosis in human hepatocytes Infect. Immun. 70 2002 6294 6301
19. D. Chelouche Lev, M. Ruiz, L. Mills, E.C. McCary, J.E. Price, and M. Bar-Eli Dacarbazine causes transcriptional upregulation of interleukin-8 and vascular endothelial growth factor in melanoma cells. A possible escape mechanism from chemotherapy Mol. Cancer Ther. 2 2003 753 763
20. F. Forozan, R. Veldman, and C.A. Ammerman Molecular cytogenetic analysis of 11 new breast cancer cell lines Br. J. Cancer 81 1999 1328 1334
21. C.G. Kleer, K.L. van Golen, and S.D. Merajver Molecular biology of breast cancer metastasis. Inflammatory breast cancer: clinical syndrome and molecular determinants Breast Cancer Res. 2 2000 423 429
22. J. Bange, E. Zwick, and A. Ullrich Molecular targets for breast cancer therapy and prevention Nat. Med. 7 2001 548 552
23. R. Hoshino, Y. Chatani, and T. Yamori Constitutive activation of the 41-/43-kDa mitogen-activated protein kinase signaling pathway in human tumors Oncogene 18 1999 813 822
24. V. Sivaraman, H.Y. Wang, G. Nuovo, and C. Malbon Hyperexpression of mitogen-activated protein kinase in human breast cancer J. Clin. Invest. 99 1997 1478 1483
25. A. Adeyinka, Y. Nui, T. Cherlet, L. Snell, P.H. Watson, and L.C. Murphy Activated mitogen-activated protein kinase expression during breast tumorigenesis and breast cancer progression Clin. Cancer Res. 8 2002 1747 1753
26. I. Vivanco, and C.L. Sawyers The phosphatidylinositol 3-kinase-AKT pathway in human cancer Nat. Rev. Cancer 2 2002 489 501
27. A.S. Clark, K. West, S. Streicher, and P.A. Dennis Constitutive and inducible Akt activity promotes resistance to chemotherapy, Trastuzumab, or Tamoxifen in breast cancer cells Mol. Cancer Ther. 1 2002 707 712
28. S.P. Davies, H. Reddy, M. Caivano, and P. Cohen Specificity and mechanisms of action of some commonly used protein kinase inhibitors Biochem. J. 351 2000 95 105
29. R. Romieu-Mourez, E. Landesman-Bollag, D.C. Seldin, and G.E. Sonenshein Protein kinase CK2 promotes aberrant activation of nuclear factor-κB, transformed phenotype,and survival of breast cancer cells Cancer Res. 62 2002 6770 6778
30. R. Romieu-Mourez, E. Landesman-Bollag, D.C. Seldin, A.M. Traish, F. Mercurio, and G.E. Sonenshein Roles of IKK kinases and protein kinase CK2 in activation of nuclear factor-κB in breast cancer Cancer Res. 61 2001 3810 3818
31. H. Fukuzawa, K. Noguchi, Y. Murakami, and Y. Uehara Mitogen-activated protein/extracellular signal-regulated kinase kinase (MEK) inhibitors restore anoikis sensitivity in human breast cancer cell lines with a constitutively activated extracellular-regulated kinase (ERK) pathway Mol. Cancer Ther. 1 2002 303 309
32. M.P. Scheid, and J.R. Woodgett Protein kinases: six degrees of separation? Curr. Biol. 10 2000 R191 R194
33. W. Kolch, G. Martiny-Baron, A. Kieser, and D. Marme Regulation of the expression of the VEGF/VPS and its receptors: role in tumor angiogenesis Breast Cancer Res. Treat. 36 1995 139 155
34. Q. Shi, Q. Xiong, X. Le, and K. Xie Regulation of interleukin-8 expression by tumor associated stress factors J. Interf. Cytok. Res. 21 2001 553 566
35. S. Huang, J.B. Robinson, A. DeGuzman, C.D. Bucana, and I.J. Fidler Blockade of NF-κB signaling inhibits angiogenesis and tumorigenicity of human ovarian cancer cells by suppressing expression of vascular endothelial growth factor and interleukin-8 Cancer Res. 60 2000 5334 5339
36. S.R. Datta, A. Brunet, and M.E. Greenberg Cellular survival: a play in three Akts Genes Dev. 13 1999 2905 2927
37. Q. Shi, X. Le, and J. Abbruzzese Constitutive Sp1 activity is essential for differential constitutive expression of vascular endothelial growth factor in human pancreatic adenocarcinoma Cancer Res. 61 2001 4143 4154
38. M. Ruiz, C.A. Pettaway, R. Song, O. Stoeltzing, L.M. Ellis, and M. Bar-Eli Activator protein 2α inhibits tumorigenicity and represses vascular endothelial growth factor transcription in prostate cancer cells Cancer Res. 64 2004 300 306
39. J.M. Gee, J.F. Robertson, I.O. Ellis, R.I. Nicholson, and H.C. Hurst Immunohistochemical analysis reveals a tumor suppressor-like role for the transcription factor AP-2 in invasive breast cancer J. Pathol. 189 1999 514 520
40. J. Pellikainen, V. Kataja, and K. Ropponen Reduced nuclear expression of transcription factor AP-2 associates with aggressive breast cancer Clin. Cancer Res. 8 2002 3487 3495
41. R.S. Kerbel, J. Yu, and J. Tran Possible mechanisms of acquired resistance to anti-angiogenic drugs: implications for the use of combination therapy approaches Cancer Metast. Rev. 20 2001 79 86
42. R. Salcedo, M. Martins-Green, B. Gertz, J.J. Oppenheim, and W.J. Murphy Combined administration of antibodies to human interleukin 8 and epidermal growth factor receptor results in increased antimetastatic effects on human breast carcinoma xenografts Clin. Cancer Res. 8 2002 2655 2665
43. L. Hu, J. Hofmann, Y. Lu, G.B. Mills, and R.B. Jaffe Inhibition of phosphatidylinositol 3′-kinase increases efficacy of paclitaxel in in vitro and in vivo ovarian cancer models Cancer Res. 62 2002 1087 1092
44. J.S. Sebolt-Leopold, D.T. Dudley, and R. Herrera Blockade of the MAP kinase pathway suppresses growth of colon tumors in vivo Nat. Med. 5 1999 810 816
45. D.M. Waterhouse, J. Rinehart, and A.A. Adjei A phase 2 study of an oral MEK inhibitor, CI-1040, in patients with advanced nonsmall-cell lung, breast, colon or pancreatic cancer Proc. Am. Soc. Clin. Oncol. 22 2003 816a